L-Carnitine. 800mg/ml – 10ml

Description

What is L-Carnitine?

L‑Carnitine is a quaternary ammonium compound synthesized endogenously from lysine and methionine, functioning as the obligate carrier that transports long‑chain fatty‑acyl groups across the inner mitochondrial membrane (via the CPT‑1/CACT/CPT‑2 carnitine shuttle) for β‑oxidation. It is an essential component of fatty‑acid energy metabolism.

Mechanism of Action

• Substrate for carnitine palmitoyltransferase‑1 (CPT1) on outer mitochondrial membrane; forms long‑chain acylcarnitine for translocation
• Translocated by carnitine‑acylcarnitine translocase (CACT); on the matrix side CPT2 regenerates acyl‑CoA for β‑oxidation
• Essential for energy production in tissues with high fatty‑acid oxidation (cardiac and skeletal muscle)
• Also buffers acetyl‑CoA pool via acetylcarnitine formation

Compound Properties

• Molecular formula: C₇H₁₅NO₃
• Molecular weight: 161.20 g/mol
• CAS: 541‑15‑1 (L‑carnitine)
• Form: Liquid preparation, 800 mg/mL concentrated solution
• Volume: 10 mL multi‑dose vial
• Source: Fermentation‑derived; ≥98% purity by HPLC

Research‑Reference Context

Published literature on L‑carnitine:

• Primary carnitine deficiency: IV/oral L‑carnitine replacement is FDA‑approved (Carnitor®) and effective (Magoulas & El‑Hattab, Orphanet Journal of Rare Diseases, 2012).
• Cardiovascular: DiNicolantonio et al., Mayo Clinic Proceedings (2013) — meta‑analysis suggesting reduced all‑cause mortality post‑MI; counter‑literature has raised concerns about TMAO production from gut metabolism of L‑carnitine.
• Weight loss/athletic performance: evidence is mixed; modest effects on exercise substrate utilization in some controlled studies.
• Secondary carnitine deficiency in dialysis patients: IV carnitine improves some endpoints.

Research Findings

• Reliable reversal of primary and secondary carnitine deficiency
• Modest metabolic effects in cardiovascular and athletic‑performance research
• Fat‑loss efficacy in non‑deficient individuals is modest at best in controlled trials

Known Side Effects Reported in Clinical Literature

• Injection‑site pain, stinging, burning
• Fishy/sulfurous body odor (trimethylamine metabolite, dose‑dependent)
• GI upset, diarrhea, nausea
• Theoretical cardiovascular concern from gut‑microbiome conversion to TMAO (Koeth et al., Nature Medicine, 2013) — clinical significance remains debated
• Rare seizure risk in predisposed individuals at very high doses

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.